{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:10:11Z","timestamp":1745554211087,"version":"3.40.4"},"reference-count":15,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intervirology"],"published-print":{"date-parts":[[2003]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; To understand the autoimmunity associated with chronic hepatitis C (CHC), we investigated autoantibodies (autoAbs) to CD69. &lt;i&gt;Methods:&lt;\/i&gt; With this aim, we tested the reactivity of serum samples from patients with CHC and asymptomatic carriers of hepatitis C virus (HCV), as well as from patients with chronic hepatitis B (CHB) and autoimmune hepatitis (AIH), to recombinant CD69 molecules. &lt;i&gt;Results:&lt;\/i&gt; Frequencies of anti-CD69 autoAbs were 38.7% in CHC, 15.8% in AIH and 12.3% in CHB. None of the tested asymptomatic HCV carriers had autoAbs to CD69. It is important clinically that the presence of anti-CD69 autoAbs was found to be associated with a poor response to interferon-\u03b1 (IFN-\u03b1) therapy. In the epitope analysis, multiple epitopes were mapped on CD69, indicating antigen-driven production of the autoAbs. &lt;i&gt;Conclusion:&lt;\/i&gt; We evidenced existence of anti-CD69 autoAbs in patients with CHC, and found that the anti-CD69 autoAb may have potential for predicting responses to IFN-\u03b1 therapy.<\/jats:p>","DOI":"10.1159\/000068126","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:40Z","timestamp":1050440740000},"page":"56-65","source":"Crossref","is-referenced-by-count":3,"title":["Autoantibodies to CD69 in Patients with Chronic Hepatitis Type C: A Candidate Marker for Predicting the Response to Interferon Therapy"],"prefix":"10.1159","volume":"46","author":[{"given":"Nahoko","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seido","family":"Ooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manae","family":"Suzuki Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Iino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusuki","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2003,2,10]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1053\/jhep.2001.22112"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1056\/NEJM199506013322202"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1053\/jhep.1996.v23.pm0008675148"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1016\/S0140-6736(96)07642-8"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1016\/S0168-8278(98)80339-5"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1056\/NEJM199904223401602"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1056\/NEJM199812243392607"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1016\/S0952-7915(00)00108-4"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1097\/00005792-200001000-00005"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1006\/jaut.1999.0360"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1002\/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2406::AID-IMMU2406>3.0.CO;2-F"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1073\/pnas.96.10.5692"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1016\/S0168-8278(99)80404-8"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.1016\/S0168-8278(98)80006-8"}],"container-title":["Intervirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/68126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:30:29Z","timestamp":1745465429000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000068126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000068126","archive":["Portico"],"relation":{},"ISSN":["0300-5526","1423-0100"],"issn-type":[{"type":"print","value":"0300-5526"},{"type":"electronic","value":"1423-0100"}],"subject":[],"published":{"date-parts":[[2003]]}}}